Literature DB >> 35813887

Estimating Costs of the HIV Comprehensive Intervention Using the Spectrum Model - China, 2015-2019.

Youran Zhang1, Lili Wang1, Zhen Jiang2, Hongjing Yan3, Xiaoxia Liu4, Jing Gu5, Guoyong Wang6, Xiaosong Cheng7, Qiyan Leng7, Qisui Long8, Zimian Liang9, Jing Wang9, Liang Liang10, Yanchao Qiu11, Lin Chen12, Hang Hong13.   

Abstract

Introduction: In order to facilitate human immunodeficiency virus (HIV) treatment and prevention, the resource needs for HIV national strategic planning in developing regions were estimated based on Spectrum, the universal HIV cost-effectiveness analysis software.
Methods: Based on the theoretical framework of Spectrum, the study developed a cost measurement tool for HIV, and calculated the cost of HIV prevention and control in 6 sampled cities in China during 2015-2019 using the Spectrum model.
Results: From 2015 to 2019, the average annual costs for HIV prevention and control for Shijiazhuang, Yantai, Ningbo, Zhenjiang, Foshan, and Wuxi cities were 46.78, 47.55, 137.49, 24.73, 74.37, and 58.30 million Chinese yuan (CNY), respectively. The per capita costs were 4.37, 6.73, 17.33, 7.77, 17.56, and 8.91 CNY, respectively. In terms of the cost structure, the ratio of preventive intervention funds to therapeutic intervention funds (antiviral treatment) varied in sampled cities. Discussion: Developing comprehensive and systematic HIV fund calculation methods can provide a research basis for rational resource allocation in the field of HIV. Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2022.

Entities:  

Keywords:  HIV; Spectrum; cost estimation

Year:  2022        PMID: 35813887      PMCID: PMC9260083          DOI: 10.46234/ccdcw2022.119

Source DB:  PubMed          Journal:  China CDC Wkly        ISSN: 2096-7071


INTRODUCTION

As China is striving to meet the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets, tracking and estimating resource needs is critical in informing financial decisions for human immunodeficiency virus (HIV) prevention and control programs. Comprehensive HIV prevention and treatment covers various target populations, such as the general population, high-risk groups, infected persons, and a series of service providers including social organizations, community health institutions, CDCs, and hospitals. Sources of funding for prevention and treatment programs include the central government, local government, charitable funds, cooperation projects, and out-of-pocket payments from individuals. The diversity of service objectives, service providers, and funding sources leads to many uncertainties in regional HIV cost calculations. Based on the theoretical framework of the international HIV cost-effectiveness analysis software Spectrum (1-2), our group developed a cost measurement and investigation tool for HIV (3) and calculated the cost of HIV prevention and control from the perspective of service suppliers. This was established by collecting and investigating the size of various populations, the actual coverage of various HIV interventions, and the unit cost of services. We estimated the cost of comprehensive HIV intervention in Shijiazhuang City from 2015 to 2019 (4). Then, based on this, we measured the HIV intervention costs of 6 cities in eastern China and compared the total costs and the composition change of HIV comprehensive intervention among these cities.

METHODS

The eastern cities of China are economically developed areas with dense populations in the secondary and tertiary sectors, large population mobility, many groups at high risk for HIV, and have better HIV intervention coverage and epidemiological records. Overall, 5 cities in eastern China including Shijiazhuang, Yantai, Ningbo, Foshan, and Wuxi (hereafter, these cities will be abbreviated as S, Y, N, F, and W, respectively) were selected according to 2 conditions: the total population was more than 3 million and the number of newly reported cases of HIV infection was more than 200 each year. In order to increase the representativeness of urban samples, the research group added Zhenjiang City (in this paper will be abbreviated as Z; located in Jiangsu Province, the same as Wuxi City) with a population of 3 million and 50 newly reported cases of HIV infection each year. Data was collected on population size, prevention of mother-to-child transmission (PMTCT), antiretroviral treatment (ART), population comprehensive prevention coverage and cost measurement, and program support. CDCs, designated treatment hospitals, and maternal and child health centers provided relevant quantitative data. If some unit costs were missing in one sampled city, we adopted the average value of available cities. If there were outliers (where the unit cost was drastically different from that in other cities), we used the average value of the cities with reasonable values. The coverage of each HIV intervention service in each city collected in this study was completely subject to the results reported and checked by the six cities. There were three sub-modules, including Demographic Model (Demproj), AIDS Impact Model (AIM), and Resource Needs Model (RNM), used for comprehensive evaluation of HIV interventions under Spectrum. DemProj Module was used to perform demographic projections by age and sex according to past fertility, mortality, and migration rates. The AIM Module was used to estimate HIV prevalence. RNM was used to generate cost estimates of various interventions (5). The employed coverages and unit costs were part of our previous work.

RESULTS

Table 1 showed that for 2015–2019, routine HIV interventions in cities S, Y, N, Z, F, and W mainly included youth, female sex workers, and men who have sex with men (MSM) focused interventions, community mobilization, condom provision, sexually transmitted infection (STI) management, voluntary counseling and testing (VCT), PMTCT, mass media, blood safety, safe injection, universal precautions, and antiretroviral therapy (ARV). The coverage related to the interventions of condom promotion, blood safety, and safe injection was unavailable because their administration departments involved other departments, such as local Family Planning Department, blood bank, and hospital.
Table 1

Average annual coverage of HIV interventions in 6 cities from 2015–2019 (in person-time).

HIV intervention S Y N Z F W
Note: N/A indicates missing data. The 6 cities include Shijiazhuang, Yantai, Ningbo, Zhenjiang, Foshan, and Wuxi, abbreviated as S, Y, N, Z, F, and W, respectively. Abbreviations: HIV=Human immunodeficiency virus; MSM=Men who have sex with men; STI=Sexually transmitted infections; VCT=Voluntary counseling and testing; PrEP=Pre-exposure prophylaxis; PMTCT=Prevention of mother-to-child transmission; PEP=Post-exposure prophylaxis; ARV=AIDS-related virus; ART=Antiretroviral therapy.
Prevention
Priority populations
Youth focused interventions3,150046,36924332,3301,426
Female sex workers and clients2,1311,53818,6462,98510,6416,072
Male sex workers and clients6200000
Cash transfersN/AN/AN/AN/AN/AN/A
Injecting drug users00099200
MSM4,3153,4098,1311,24723,2057,660
Community mobilization255,351196,606376,180857,149199,889171,267
Service delivery
Condom provisionN/AN/AN/AN/AN/AN/A
STI management6175645,911678,8591,096
VCT21,19813,51916,3796,7394,6314,860
PrEP000000
PMTCT214145
Mass media829,7201,255,575839,14997,008207,673N/A
Health care
Blood safety294,311595,350N/AN/AN/A74,229
PEP067552000
Safe injectionN/AN/AN/AN/AN/AN/A
Universal precautions54,78141,29332,59314,70330,78634,260
Care and treatment services
ARV therapy1,3796733,2518151,982398
Non-ART care and prophylaxis608371626153527696
In order to make the costs more comparable, the gross domestic product (GDP) deflators of the six cities were obtained by referring to the regional GDP index ( Supplementary Table S1, available in http://weekly.chinacdc.cn/). The 2019 GDP deflator was adopted to modify the projected costs. Then, the total and average annual cost of each intervention for each city was calculated. There was an imbalance in the total costs and per-capita of HIV funds among cities (Table 2). From 2015 to 2019, the average annual costs of S, Y, N, Z, F, and W were 46.78 million Chinese yuan (CNY), 47.55 million CNY, 137.49 million CNY, 24.73 million CNY, 74.37 million CNY, and 58.30 million CNY, respectively. The per capita costs were 4.37 CNY, 6.73 CNY, 17.33 CNY, 7.77 CNY, 17.56 CNY, and 8.91 CNY, respectively. City N had the largest cost input in all service categories including priority population, service delivery, health care, treatment services and program support. City N reached 17.37 CNY per capita, city F reached 17.56 CNY per capita, and city S reached 4.37 CNY per capita. We plotted the three categories of cost results (prevention, treatment, and program support) displayed by Spectrum and calculated the cost ratio of preventive and therapeutic interventions.
Table 2

Costs of HIV interventions in 6 cities from 2015–2019 (in million CNY).

Cost for HIV Intervention S Y N Z F W
Note: N/A indicates missing data. The 6 cities include Shijiazhuang, Yantai, Ningbo, Zhenjiang, Foshan, and Wuxi, abbreviated as S, Y, N, Z, F, and W, respectively. Abbreviations: HIV=Human immunodeficiency virus; CNY=Chinese yuan; MSM=Men who have sex with men; STI=Sexually transmitted infection; VCT=Voluntary counseling and testing; PrEP=Pre-exposure prophylaxis; PMTCT=Prevention of mother-to-child transmission; PEP=Post-exposure prophylaxis; ARV=AIDS-related virus; ART=Antiretroviral therapy; HR=Human resource. * The cost of male sex workers and clients in city S was not 0, but 2,654 CNY. The unit cost of this indicator in city S was quite different from the other cities, therefore, the average value of other cities filled in the unit cost had been taken. § To ensure the comparability of total costs in all cities, i.e., all sub cost items in 6 cities were the same, the total costs in this study did not include the costs of condom provision, PMTCT, blood safety, and laboratory equipment.
Prevention7.2927.9033.968.9530.2616.15
 Priority populations0.962.6114.800.8814.614.76
  Youth focused interventions0.190.002.540.042.830.12
  Female sex workers and clients0.040.021.960.010.530.62
  Male sex workers and clients0.00*0.000.000.000.000.00
  Cash transfers0.000.000.000.000.000.00
  Injecting drug users0.000.000.000.590.000.00
  MSM0.410.370.850.071.230.98
  Community mobilization0.322.239.450.1710.013.03
 Service delivery§1.594.7812.152.966.891.54
  Condom provision§204.5430.4518.095.72139.80111.72
  STI management0.400.307.210.036.100.56
  VCT0.944.284.822.860.360.98
  Male circumcision0.000.000.000.000.000.00
  PrEP0.000.000.000.000.000.00
  PMTCT§8.370.080.760.181.510.04
  Mass media0.260.200.120.070.430.00
 Health care§4.7420.517.015.118.769.85
  Blood safety§110.4035.55N/AN/AN/A6.02
  PEP0.000.170.150.000.000.00
  Safe injectionN/AN/AN/AN/AN/AN/A
  Universal precautions4.7420.346.865.118.769.85
Care and treatment services37.1617.5850.9013.0636.9534.67
 ARV therapy17.068.4733.587.7718.479.43
 Non-ART care and prophylaxis20.109.1017.325.3018.4825.25
Program support§2.322.0852.642.717.167.48
 Enabling environment0.000.000.000.000.000.00
 Program management1.280.7144.400.800.935.19
 Research0.000.000.000.000.000.00
 Monitoring and evaluation0.040.070.000.070.120.41
 Strategic communication0.000.000.000.000.000.00
 Logistics0.060.375.920.413.080.83
 Program-level HR0.810.852.281.342.300.90
 Training0.130.070.040.100.730.15
 Laboratory equipment§1.362.83.0127.1130.97N/A
Total millions of CNY§46.7847.55137.4924.7374.3758.30
Total populations10,699,3147,065,3627,936,0823,183,8324,235,7916,543,320
Per capita HIV intervention cost (CNY)4.376.7317.337.7717.568.91
Cost ratio of prevention to treatment0.201.590.670.690.820.47
Figure 1 showed that the comparable per capita cost of HIV finance increased steadily during 2015–2019 in all 6 cities. City N started at a high level and continued improving rapidly. The total cost ratio of prevention to treatment in 6 cities decreased from 0.79 in 2015 to 0.58 in 2019. The 6 cities had different manifestations in the cost changes for prevention and treatment interventions: 1) fluctuating: in city Y, the funds for prevention and treatment were in a stable fluctuating state. The ratio of prevention/treatment expenditure was around 1.8–1.4; 2) rapid increase in ARV: in city N, the investment of preventive intervention funds was stable, the cost of ARV funds increased from 24.79 million CNY in 2015 to 69.51 million CNY in 2019, and the ratio of prevention to treatment funds showed a rapid downward trend (from 1.25 in 2015 to 0.50 in 2019); 3) steady increase in ARV: in city Z, F, and W, the investment of preventive intervention funds was stable, the cost of ARV funds increased steadily, and the ratio of prevention/treatment funds showed a steady downward trend (from 0.88, 0.92, and 0.54 in 2015 to 0.59, 0.72, and 0.42 in 2019); 4) synchronous growth type: in city S, prevention and treatment funds maintained a synchronous growth trend (from 0.13 in 2015 to 0.20 in 2019).
Figure 1

Per capita cost and cost ratio of prevention to treatment of 6 cities from 2015 to 2019.

Per capita cost and cost ratio of prevention to treatment of 6 cities from 2015 to 2019. Note: The 6 cities include Shijiazhuang, Yantai, Ningbo, Zhenjiang, Foshan, and Wuxi, abbreviated as S, Y, N, Z, F, and W, respectively. Abbreviation: CNY=Chinese yuan.

DISCUSSION

A mature model with standardized data collection and information processing can generate more reliable estimates. Through standardized reports, the research results are reliable for decision-makers (6-7). Particularly, it may help to reasonably estimate the resources needed to expand, maintain, or replicate successful interventions at a local or national level. Multiple data collection sources and incomplete information greatly increased the complexity of HIV disease-tracking modeling. Data reported by different departments and institutions may often conflict with each other. Developed jointly by the United Nations Programme on HIV/AIDS and other national teams, Spectrum software can estimate the cost of HIV/AIDS based on the mathematical model established by regional HIV/AIDS epidemic data and intervention program coverage (8). This provides a tool to calculate and compare HIV funds among subnational regions in China. Our research reflected that HIV prevention and control funds continued to grow, but there was a regional imbalance in sampled cities. Based on the data of 2019, the comparable HIV intervention total cost in 6 cities adjusted by the GDP deflator showed an upward trend, indicating that each city had continuously increased investment in HIV prevention and control. In the most economically developed provinces, Guangdong and Zhejiang, the HIV prevention and control costs of the sampled cities were significantly higher than those of other cities. Our research suggested that it is necessary to explore the correlation among preliminary work indicators, fund allocation, and subsequent intervention coverage and quality in the future. Differentiating reasonable and unreasonable factors of regional resource allocation will help to provide evidence for equitable and efficient resource allocation (9). The distribution structure of funds for prevention and treatment must be balanced. With the continuous scaling-up of ARV, post-exposure prophylaxis (PEP), pre-exposure prophylaxis (PrEP), and other proven effective therapeutic interventions, investment in this area has increased rapidly worldwide. From 2015 to 2019, it was determined that HIV funding in these 6 cities was mainly due to the rapid growth of ARV costs. Evidence from the past 40 years indicated that scientific innovation, research, funding, activism, and policies were all central components of HIV messaging in ending HIV (10). It is necessary to simulate the list of prioritized interventions with high cost-effectiveness combined with the local population size, characteristics and HIV epidemic trend. An optimized HIV resource reallocation model may provide a reference for future intensive HIV investments (11-14). This study was subject to some limitations. First, in the current tool, the costs were classified according to intervention services, which was different from the actual situation. For example, the provision of condoms involved multiple departments. It was difficult to collect multi-source data and may have resulted in underestimating related costs. In future studies, cost measurement tools consistent with the implementation will be more operable and more accurate. Second, the current cost measurement tools were still difficult to distinguish between the quantity and quality of HIV interventions and quantify each dimension. For example, there are great differences between the number of people receiving standardized STI management coverage and the number of people receiving STI treatment. This study estimated the cost according to the former indicators, which may have underestimated the total expenditure of STI treatment and management. The distinction and quantification of the “quality” and “quantity” of HIV intervention will increase the accuracy of cost estimation in the next step.

Conflicts of interest

No conflicts of interest.

REFERENCES

Shijiazhuang Bureau of Statistics, Shijiazhuang Investigation Team of National Bureau of Statistics. Shijiazhuang Statistical Yearbook in 2020. Beijing: China Statistics Press. 2021. http://tjj.sjz.gov.cn/col/1584345186126/2021/07/21/1626855580453.html. [2021-6-26]. (In Chinese). Yantai Bureau of Statistics. Yantai Statistical Yearbook in 2020. Yantai: Yantai Bureau of Statistics. 2020. http://tjj.yantai.gov.cn/art/2021/1/11/art_118_2876126.html. [2021-6-26]. (In Chinese). Ningbo Bureau of Statistics, Ningbo Survey Team of National Bureau of Statistics. Ningbo Statistical Yearbook in 2020. Beijing: China Statistics Press. 2020. http://vod.ningbo.gov.cn:88/nbtjj/tjnj/2020nbnj/indexch.htm. [2021-6-26]. (In Chinese). Zhenjiang Bureau of Statistics, Zhenjiang Survey Team of National Bureau of Statistics. Zhenjiang Statistical Yearbook in 2020. Beijing: China Statistics Press. 2020. http://find.nlc.cn/search/showDocDetails?docId=-8904574365069863899&dataSource=ucs01&query=%E9%95%87%E6%B1%9F%E7%BB%9F%E8%AE%A1%E5%B9%B4%E9%89%B42020. [2021-6-26]. (In Chinese). Foshan Bureau of Statistics. Foshan Statistical Yearbook in 2020. http://www.foshan.gov.cn/attachment/0/153/153028/4654170.zip. [2021-6-26]. (In Chinese). Wuxi Bureau of Statistics, Wuxi Survey Team of National Bureau of Statistics. Wuxi Statistical Yearbook in 2020. Beijing: China Statistics Press. 2020. http://find.nlc.cn/search/showDocDetails?docId=3013650469888556520&dataSource=ucs01&query=%E6%97%A0%E9%94%A1%E7%BB%9F%E8%AE%A1%E5%B9%B4%E9%89%B42020. [2021-6-26]. (In Chinese).
Table S1

GDP deflator of 6 cities from 2015–2019.

City Year Gross regional product (Current year price,Unit: 100 million CNY) Regional GDP index Regional GDP deflator
Note: Data source: Statistical Yearbook of 6 cities; Shijiazhuang Statistical Yearbook in 2020 (1); Yantai Statistical Yearbook in 2020 (2); Ningbo Statistical Yearbook in 2020 (3); Zhenjiang Statistical Yearbook in 2020 (4); Foshan Statistical Yearbook in 2020 (5); and Wuxi Statistical Yearbook in 2020 (6). Abbreviations: GDP=Gross domestic product; CNY=Chinese yuan.
S20155,440.60100.001.23
20165,857.80106.801.24
20176,460.90114.491.24
20186,082.60122.961.12
20195,809.90131.201.00
Y20156,086.49100.001.02
20166,455.84107.701.01
20176,762.00114.591.01
20187,184.43121.810.99
20197,653.45128.511.00
N20158,295.35100.000.91
20168,972.83107.200.92
201710,146.55115.670.92
201811,193.14123.771.00
201911,985.12132.181.00
Z20153,088.47100.000.97
20163,435.73109.300.99
20173,847.79117.170.99
20183,847.79120.801.00
20194,077.32127.811.00
F20158,107.60100.001.00
20168,756.31107.911.00
20179,382.16116.511.00
20189,976.72123.920.99
201910,751.02132.471.00
W20158,681.37100.000.97
20169,340.16107.500.97
201710,313.07115.460.97
201811,202.98124.001.01
201911,803.32132.181.00
  11 in total

Review 1.  Cost of Tuberculosis Diagnosis and Treatment in Patients with HIV: A Systematic Literature Review.

Authors:  Noemia Teixeira de Siqueira-Filha; Rosa Legood; Aracele Cavalcanti; Andreia Costa Santos
Journal:  Value Health       Date:  2017-10-18       Impact factor: 5.725

2.  New HIV infections from blood transfusions averted in 28 countries supported by PEPFAR blood safety programs, 2004-2015.

Authors:  Fatima D Mili; Yu Teng; Ray W Shiraishi; Junping Yu; Naomi Bock; Bakary Drammeh; D Heather Watts; Irene Benech
Journal:  Transfusion       Date:  2021-01-28       Impact factor: 3.157

3.  The global Optima HIV allocative efficiency model: targeting resources in efforts to end AIDS.

Authors:  Sherrie L Kelly; Rowan Martin-Hughes; Robyn M Stuart; Xiao F Yap; David J Kedziora; Kelsey L Grantham; S Azfar Hussain; Iyanoosh Reporter; Andrew J Shattock; Laura Grobicki; Hassan Haghparast-Bidgoli; Jolene Skordis-Worrall; Zofia Baranczuk; Olivia Keiser; Janne Estill; Janka Petravic; Richard T Gray; Clemens J Benedikt; Nicole Fraser; Marelize Gorgens; David Wilson; Cliff C Kerr; David P Wilson
Journal:  Lancet HIV       Date:  2018-03-11       Impact factor: 12.767

4.  Ending the HIV epidemic in the USA: an economic modelling study in six cities.

Authors:  Bohdan Nosyk; Xiao Zang; Emanuel Krebs; Benjamin Enns; Jeong E Min; Czarina N Behrends; Carlos Del Rio; Julia C Dombrowski; Daniel J Feaster; Matthew Golden; Brandon D L Marshall; Shruti H Mehta; Lisa R Metsch; Ankur Pandya; Bruce R Schackman; Steven Shoptaw; Steffanie A Strathdee
Journal:  Lancet HIV       Date:  2020-03-05       Impact factor: 12.767

5.  Building resource constraints and feasibility considerations in mathematical models for infectious disease: A systematic literature review.

Authors:  Fiammetta M Bozzani; Anna Vassall; Gabriela B Gomez
Journal:  Epidemics       Date:  2021-03-13       Impact factor: 4.396

6.  A 10-year economic analysis of HIV management in Greece: evidence of efficient resource allocation.

Authors:  Kostas Athanasakis; Vasiliki Naoum; Panagiota Naoum; Nikos Nomikos; Dorina Theodoratou; John Kyriopoulos
Journal:  Curr Med Res Opin       Date:  2021-12-23       Impact factor: 2.580

7.  What Is Required to End the AIDS Epidemic as a Public Health Threat by 2030? The Cost and Impact of the Fast-Track Approach.

Authors:  John Stover; Lori Bollinger; Jose Antonio Izazola; Luiz Loures; Paul DeLay; Peter D Ghys
Journal:  PLoS One       Date:  2016-05-09       Impact factor: 3.240

Review 8.  Updates to the Spectrum/AIM model for estimating key HIV indicators at national and subnational levels.

Authors:  John Stover; Robert Glaubius; Lynne Mofenson; Caitlin M Dugdale; Mary-Ann Davies; Gabriela Patten; Constantin Yiannoutsos
Journal:  AIDS       Date:  2019-12-15       Impact factor: 4.177

9.  Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors:  Christopher J L Murray; Katrina F Ortblad; Caterina Guinovart; Stephen S Lim; Timothy M Wolock; D Allen Roberts; Emily A Dansereau; Nicholas Graetz; Ryan M Barber; Jonathan C Brown; Haidong Wang; Herbert C Duber; Mohsen Naghavi; Daniel Dicker; Lalit Dandona; Joshua A Salomon; Kyle R Heuton; Kyle Foreman; David E Phillips; Thomas D Fleming; Abraham D Flaxman; Bryan K Phillips; Elizabeth K Johnson; Megan S Coggeshall; Foad Abd-Allah; Semaw Ferede Abera; Jerry P Abraham; Ibrahim Abubakar; Laith J Abu-Raddad; Niveen Me Abu-Rmeileh; Tom Achoki; Austine Olufemi Adeyemo; Arsène Kouablan Adou; José C Adsuar; Emilie Elisabet Agardh; Dickens Akena; Mazin J Al Kahbouri; Deena Alasfoor; Mohammed I Albittar; Gabriel Alcalá-Cerra; Miguel Angel Alegretti; Zewdie Aderaw Alemu; Rafael Alfonso-Cristancho; Samia Alhabib; Raghib Ali; Francois Alla; Peter J Allen; Ubai Alsharif; Elena Alvarez; Nelson Alvis-Guzman; Adansi A Amankwaa; Azmeraw T Amare; Hassan Amini; Walid Ammar; Benjamin O Anderson; Carl Abelardo T Antonio; Palwasha Anwari; Johan Arnlöv; Valentina S Arsic Arsenijevic; Ali Artaman; Rana J Asghar; Reza Assadi; Lydia S Atkins; Alaa Badawi; Kalpana Balakrishnan; Amitava Banerjee; Sanjay Basu; Justin Beardsley; Tolesa Bekele; Michelle L Bell; Eduardo Bernabe; Tariku Jibat Beyene; Neeraj Bhala; Ashish Bhalla; Zulfiqar A Bhutta; Aref Bin Abdulhak; Agnes Binagwaho; Jed D Blore; Berrak Bora Basara; Dipan Bose; Michael Brainin; Nicholas Breitborde; Carlos A Castañeda-Orjuela; Ferrán Catalá-López; Vineet K Chadha; Jung-Chen Chang; Peggy Pei-Chia Chiang; Ting-Wu Chuang; Mercedes Colomar; Leslie Trumbull Cooper; Cyrus Cooper; Karen J Courville; Benjamin C Cowie; Michael H Criqui; Rakhi Dandona; Anand Dayama; Diego De Leo; Louisa Degenhardt; Borja Del Pozo-Cruz; Kebede Deribe; Don C Des Jarlais; Muluken Dessalegn; Samath D Dharmaratne; Uğur Dilmen; Eric L Ding; Tim R Driscoll; Adnan M Durrani; Richard G Ellenbogen; Sergey Petrovich Ermakov; Alireza Esteghamati; Emerito Jose A Faraon; Farshad Farzadfar; Seyed-Mohammad Fereshtehnejad; Daniel Obadare Fijabi; Mohammad H Forouzanfar; Urbano Fra Paleo; Lynne Gaffikin; Amiran Gamkrelidze; Fortuné Gbètoho Gankpé; Johanna M Geleijnse; Bradford D Gessner; Katherine B Gibney; Ibrahim Abdelmageem Mohamed Ginawi; Elizabeth L Glaser; Philimon Gona; Atsushi Goto; Hebe N Gouda; Harish Chander Gugnani; Rajeev Gupta; Rahul Gupta; Nima Hafezi-Nejad; Randah Ribhi Hamadeh; Mouhanad Hammami; Graeme J Hankey; Hilda L Harb; Josep Maria Haro; Rasmus Havmoeller; Simon I Hay; Mohammad T Hedayati; Ileana B Heredia Pi; Hans W Hoek; John C Hornberger; H Dean Hosgood; Peter J Hotez; Damian G Hoy; John J Huang; Kim M Iburg; Bulat T Idrisov; Kaire Innos; Kathryn H Jacobsen; Panniyammakal Jeemon; Paul N Jensen; Vivekanand Jha; Guohong Jiang; Jost B Jonas; Knud Juel; Haidong Kan; Ida Kankindi; Nadim E Karam; André Karch; Corine Kakizi Karema; Anil Kaul; Norito Kawakami; Dhruv S Kazi; Andrew H Kemp; Andre Pascal Kengne; Andre Keren; Maia Kereselidze; Yousef Saleh Khader; Shams Eldin Ali Hassan Khalifa; Ejaz Ahmed Khan; Young-Ho Khang; Irma Khonelidze; Yohannes Kinfu; Jonas M Kinge; Luke Knibbs; Yoshihiro Kokubo; S Kosen; Barthelemy Kuate Defo; Veena S Kulkarni; Chanda Kulkarni; Kaushalendra Kumar; Ravi B Kumar; G Anil Kumar; Gene F Kwan; Taavi Lai; Arjun Lakshmana Balaji; Hilton Lam; Qing Lan; Van C Lansingh; Heidi J Larson; Anders Larsson; Jong-Tae Lee; James Leigh; Mall Leinsalu; Ricky Leung; Yichong Li; Yongmei Li; Graça Maria Ferreira De Lima; Hsien-Ho Lin; Steven E Lipshultz; Shiwei Liu; Yang Liu; Belinda K Lloyd; Paulo A Lotufo; Vasco Manuel Pedro Machado; Jennifer H Maclachlan; Carlos Magis-Rodriguez; Marek Majdan; Christopher Chabila Mapoma; Wagner Marcenes; Melvin Barrientos Marzan; Joseph R Masci; Mohammad Taufiq Mashal; Amanda J Mason-Jones; Bongani M Mayosi; Tasara T Mazorodze; Abigail Cecilia Mckay; Peter A Meaney; Man Mohan Mehndiratta; Fabiola Mejia-Rodriguez; Yohannes Adama Melaku; Ziad A Memish; Walter Mendoza; Ted R Miller; Edward J Mills; Karzan Abdulmuhsin Mohammad; Ali H Mokdad; Glen Liddell Mola; Lorenzo Monasta; Marcella Montico; Ami R Moore; Rintaro Mori; Wilkister Nyaora Moturi; Mitsuru Mukaigawara; Kinnari S Murthy; Aliya Naheed; Kovin S Naidoo; Luigi Naldi; Vinay Nangia; K M Venkat Narayan; Denis Nash; Chakib Nejjari; Robert G Nelson; Sudan Prasad Neupane; Charles R Newton; Marie Ng; Muhammad Imran Nisar; Sandra Nolte; Ole F Norheim; Vincent Nowaseb; Luke Nyakarahuka; In-Hwan Oh; Takayoshi Ohkubo; Bolajoko O Olusanya; Saad B Omer; John Nelson Opio; Orish Ebere Orisakwe; Jeyaraj D Pandian; Christina Papachristou; Angel J Paternina Caicedo; Scott B Patten; Vinod K Paul; Boris Igor Pavlin; Neil Pearce; David M Pereira; Aslam Pervaiz; Konrad Pesudovs; Max Petzold; Farshad Pourmalek; Dima Qato; Amado D Quezada; D Alex Quistberg; Anwar Rafay; Kazem Rahimi; Vafa Rahimi-Movaghar; Sajjad Ur Rahman; Murugesan Raju; Saleem M Rana; Homie Razavi; Robert Quentin Reilly; Giuseppe Remuzzi; Jan Hendrik Richardus; Luca Ronfani; Nobhojit Roy; Nsanzimana Sabin; Mohammad Yahya Saeedi; Mohammad Ali Sahraian; Genesis May J Samonte; Monika Sawhney; Ione J C Schneider; David C Schwebel; Soraya Seedat; Sadaf G Sepanlou; Edson E Servan-Mori; Sara Sheikhbahaei; Kenji Shibuya; Hwashin Hyun Shin; Ivy Shiue; Rupak Shivakoti; Inga Dora Sigfusdottir; Donald H Silberberg; Andrea P Silva; Edgar P Simard; Jasvinder A Singh; Vegard Skirbekk; Karen Sliwa; Samir Soneji; Sergey S Soshnikov; Chandrashekhar T Sreeramareddy; Vasiliki Kalliopi Stathopoulou; Konstantinos Stroumpoulis; Soumya Swaminathan; Bryan L Sykes; Karen M Tabb; Roberto Tchio Talongwa; Eric Yeboah Tenkorang; Abdullah Sulieman Terkawi; Alan J Thomson; Andrew L Thorne-Lyman; Jeffrey A Towbin; Jefferson Traebert; Bach X Tran; Zacharie Tsala Dimbuene; Miltiadis Tsilimbaris; Uche S Uchendu; Kingsley N Ukwaja; Selen Begüm Uzun; Andrew J Vallely; Tommi J Vasankari; N Venketasubramanian; Francesco S Violante; Vasiliy Victorovich Vlassov; Stein Emil Vollset; Stephen Waller; Mitchell T Wallin; Linhong Wang; XiaoRong Wang; Yanping Wang; Scott Weichenthal; Elisabete Weiderpass; Robert G Weintraub; Ronny Westerman; Richard A White; James D Wilkinson; Thomas Neil Williams; Solomon Meseret Woldeyohannes; John Q Wong; Gelin Xu; Yang C Yang; Yuichiro Yano; Gokalp Kadri Yentur; Paul Yip; Naohiro Yonemoto; Seok-Jun Yoon; Mustafa Younis; Chuanhua Yu; Kim Yun Jin; Maysaa El Sayed Zaki; Yong Zhao; Yingfeng Zheng; Maigeng Zhou; Jun Zhu; Xiao Nong Zou; Alan D Lopez; Theo Vos
Journal:  Lancet       Date:  2014-07-22       Impact factor: 79.321

10.  Optimal allocation of HIV resources among geographical regions.

Authors:  David J Kedziora; Robyn M Stuart; Jonathan Pearson; Alisher Latypov; Rhodri Dierst-Davies; Maksym Duda; Nata Avaliani; David P Wilson; Cliff C Kerr
Journal:  BMC Public Health       Date:  2019-11-12       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.